National Cancer Institute; Notice of Closed Meeting, 80733 [2023-25619]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 222 / Monday, November 20, 2023 / Notices
Regulations’’). At the conclusion of the
Exclusion Period, Respondent agrees to
have her research supervised for a
period of two (2) years (the
‘‘Supervision Period’’). During the
Supervision Period, prior to the
submission of an application for PHS
support for a research project on which
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity in PHS-supported
research, Respondent will submit a plan
for supervision of Respondent’s duties
to ORI for approval. The supervision
plan must be designed to ensure the
integrity of Respondent’s research.
Respondent will not participate in any
PHS-supported research until such a
supervision plan is approved by ORI.
Respondent will comply with the
agreed-upon supervision plan.
(2) During the Exclusion Period,
Respondent will not apply for, permit
her name to be used on an application
for, receive, or be supported by funds of
the United States Government and its
agencies made available through
contracts, subcontracts, or covered
transactions.
(3) During the Supervision Period, the
requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution including
Respondent’s supervisor or
collaborators will provide oversight and
guidance. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved. The review will include a
discussion with Respondent of the
primary data represented in those
documents and will include a
certification to ORI that the data
presented in the proposed application,
report, manuscript, or abstract are
supported by the research record.
(4) During the Supervision Period,
Respondent will ensure that any
institution employing her submits, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
VerDate Sep<11>2014
17:42 Nov 17, 2023
Jkt 262001
procedures, and methodology are
accurately reported and not plagiarized
in the application, report, manuscript,
or abstract.
(5) If no supervision plan is provided
to ORI, Respondent will provide
certification to ORI at the conclusion of
the Supervision Period that her
participation was not proposed on a
research project for which an
application for PHS support was
submitted and that she has not
participated in any capacity in PHSsupported research.
(6) During the Exclusion and
Supervision Periods, Respondent will
exclude herself voluntarily from serving
in any advisory or consultant capacity
to PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee.
Dated: November 15, 2023.
Sheila Garrity,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
[FR Doc. 2023–25603 Filed 11–17–23; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–3: NCI
Clinical and Translational Cancer Research.
Date: February 21–22, 2024.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W612, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Prashant Sharma, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W612, Rockville,
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
80733
Maryland 20850, 240–275–6351,
prashant.sharma@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 15, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–25619 Filed 11–17–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2023–0830]
National Merchant Mariner Medical
Advisory Committee; December 2023
Virtual Meeting
United States Coast Guard,
Department of Homeland Security.
ACTION: Notice of open Federal advisory
committee virtual meeting.
AGENCY:
The National Merchant
Mariner Medical Advisory Committee
(Committee) will conduct a virtual
meeting to discuss matters relating to
medical certification determinations for
issuance of licenses, certificates of
registry, and merchant mariners’
documents, medical standards, and
guidelines for the physical
qualifications of operators of
commercial vessels, medical examiner
education, and medical research. The
virtual meeting will be open to the
public.
SUMMARY:
Meeting: The Committee will
meet virtually on Tuesday, December
19, 2023, from noon until 3:00 p.m.
Eastern Standard Time, (EST). The
virtual meeting may adjourn early if the
Committee has completed its business.
Comments and supporting
documentation: To ensure your
comments are received by Committee
members before the virtual meeting,
submit your written comments no later
than December 12, 2023.
ADDRESSES: To join the virtual meeting
or to request special accommodations,
contact the individual listed in the FOR
FURTHER INFORMATION CONTACT section
no later than 1 p.m. EST on December
12, 2023, to obtain the needed
information.
DATES:
E:\FR\FM\20NON1.SGM
20NON1
]]>Agencies
[Federal Register Volume 88, Number 222 (Monday, November 20, 2023)]
[Notices]
[Page 80733]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25619]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; SEP-3: NCI Clinical and Translational Cancer Research.
Date: February 21-22, 2024.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W612, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Prashant Sharma, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W612, Rockville, Maryland 20850, 240-275-6351,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 15, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-25619 Filed 11-17-23; 8:45 am]
BILLING CODE 4140-01-P
